Taysha Gene Therapies (TSHA) Invested Capital (2020 - 2026)

Taysha Gene Therapies (TSHA) posted Invested Capital of $40.0 million for Q3 2023, up 66566.67% sequentially from $60000.0 in Q3 2020.

Analysis

Taysha Gene Therapies (TSHA) Invested Capital (2020 - 2026) Analysis & Trends

Taysha Gene Therapies has reported Invested Capital for 2 years, with the latest figure at $40.0 million in Q3 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	Taysha Gene Therapies	2.06 Bn	2.06 Bn	-	436.53 Mn

Historic Data

Download Data